Page 2 - குரோன் பெருங்குடல் அழற்சி அடித்தளம் ஆஃப் அமெரிக்கா News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Phase 3 Maintenance Results Show Patients with Crohn s Disease Receiving Risankizumab (SKYRIZI®) Achieved Endoscopic Response and Clinical Remission at One Year - In Crohn s disease patients with clinical response to risankizumab IV induction treatment, a significantly greater proportion of patients treated with risankizumab 360 mg SC achieved endoscopic response and clinical remission at one year (52 weeks) versus those who were withdrawn from risankizumab (control group)[1] - The overall safety results in this study were generally consistent with the known safety profile of risankizumab, with no new safety risks observed[1-7] - Risankizumab (SKYRIZI), an interleukin-23 (IL-23) inhibitor, is being evaluated as a treatment for adults with moderate to severe Crohn s disease and several other immune-mediated conditions[1,8-10]

United statesGastroenterol hepatolAccess economics ptyDrug administrationBoehringer ingelheimExchange commissionAbbvie incCrohn colitis foundation of americaWorld congressDisease activity indexEuropean commissionTreatment evaluationFull prescribing informationMedication guideAllergan aestheticsPrivate securities litigation reform act